Skip to main content
SpringerLink
Log in
Book cover

Immunoendocrinology: Scientific and Clinical Aspects pp 399–413Cite as

Addison’s Disease

  • Chapter
  • First Online:

Part of the book series: Contemporary Endocrinology ((COE))

Summary

Autoimmune Addison’s disease (AAD) represents 70–90% of all cases of primary adrenal insufficiency (PAI) in western countries and Japan. The adrenal autoimmune process is made evident by the appearance of autoantibodies, directed against steroid-21-hydroxylase (21OHAb), the gold marker to identify AAD in patients with clinical and biochemical signs of adrenal insufficiency. 21OHAb have no major pathogenic role, and the disease is thought to be caused by a cell-mediated immune process. In 21OHAb-negative patients, adrenal imaging and very long-chain fatty acids determination should be performed to exclude other causes of PAI such as posttuberculosis Addison’s disease or X-linked adrenoleukodystrophy. AAD is a major component of autoimmune polyendocrine syndrome (APS) type 1 and type 2. Isolated AAD and APS2-related AAD are strongly associated with HLA-DRB1*0301–DQA1*0501–DQB1*0201 (DR3–DQ2) and DRB1*04–DQA1*0301–DQB1*0302 (DR4–DQ8). HLA-DRB1*0403 is strongly protective for the development of AAD. Other genetic factors that contribute to the risk of AAD include MICA5.1, and the polymorphisms of the CTLA-4, PTPN22, and MHC2TA genes. Around two-thirds of AAD subjects show clinical or biochemical signs of other autoimmune diseases, the most common being thyroid autoimmune diseases, type 1 diabetes mellitus, and primary ovarian insufficiency. Presence of 21OHAb in subjects with no clinical signs of adrenal insufficiency and with normal basal cortisol levels identifies the so-called subclinical AAD. In subjects with subclinical AAD, a stimulation test with 1 μg of synthetic ACTH should be performed to discriminate between an early and potentially reversible adrenal dysfunction and a progressive form of the disease.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   249.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Oelkers W. Adrenal insufficiency. N Engl J Med 1996;335:1206–1212.

    Article  PubMed  CAS  Google Scholar 

  2. Aubourg P. On the front of X-linked adrenoleukodystrophy. Neurochem Res 1999;24:515–520.

    Article  PubMed  CAS  Google Scholar 

  3. McCabe ER. DAX1: increasing complexity in the roles of this novel nuclear receptor. Mol Cell Endocrinol 2007;265–266:179–182.

    Article  PubMed  Google Scholar 

  4. Achermann JC, Ito M, Ito M, Hindmarsch PC, Jameson JL. A mutation in the gene encoding steroidogenic factor-1 causes XY sex reversal and adrenal failure in humans. Nat Genet 1999;22:125–126.

    Article  PubMed  CAS  Google Scholar 

  5. Clark AJ, McLoughlin L, Grossman A. Familial glucocorticoid deficiency associated with point mutation in the adrenocorticotropin receptor. Lancet 1993;341:461–462.

    Article  PubMed  CAS  Google Scholar 

  6. Weber A, Wienker TF, Jung M, Easton D, Dean HJ, Heinrichs C, Reis A, Clark A. Linkage of the gene for the triple A syndrome to chromosome 12q13 near the type II keratin gene cluster. Hum Mol Genet 1996;5:2061–2066.

    Article  PubMed  CAS  Google Scholar 

  7. North K, Korson MS, Krawiecki N, Shoffner JM, Holm IA. Oxidative phosphorylation defect associated with primary adrenal insufficiency. J Pediatr 1996;128:688–692.

    Article  PubMed  CAS  Google Scholar 

  8. Andersson HC, Frentz J, Martínez JE, Tuck-Muller CM, Bellizaire J. Adrenal insufficiency in Smith–Lemli–Opitz syndrome. Am J Med Genet 1999;82:382–384.

    Article  PubMed  CAS  Google Scholar 

  9. Laureti S, Vecchi L, Santeusanio F, Falorni A. Is the prevalence of Addison’s disease underestimated? J Clin Endocrinol Metab 1999;84:1762.

    Article  PubMed  CAS  Google Scholar 

  10. Lovas K, Husebye ES. High prevalence and increasing incidence of Addison’s disease in Western Norway. Clin Endocrinol 2002;56:787–791.

    Article  Google Scholar 

  11. Laureti S, Santeusanio F, Falorni A. Recent advances in the diagnosis and therapy of primary adrenal insufficiency. Curr Med Chem Immunol Endocr Metab Agents 2002;2:251–272.

    Article  CAS  Google Scholar 

  12. Cooper MS, Stewart PM. Corticosteroid insufficiency in acutely ill patients. N Engl J Med 2003;348:727–734.

    Article  PubMed  CAS  Google Scholar 

  13. Newell-Price J, Whiteman M, Rostami-Hodjegan A, Darzy K, Shalet S, Tucker GT, Ross RJM. Modified-release hydrocortisone for circadian therapy: a proof-of-principle study in dexamethasone-suppressed normal volunteers. Clin Endocrinol 2008;68:130–135.

    Article  CAS  Google Scholar 

  14. Falorni A, Laureti S, Santeusanio F. Autoantibodies in polyendocrine syndrome type II. Endocrinol Metab Clin North Am 2002;31:369–389.

    Article  PubMed  CAS  Google Scholar 

  15. Betterle C, Dal Pra C, Mantero F, Zanchetta R. Autoimmune adrenal insufficiency and autoimmune polyendocrine syndromes: autoantibodies, autoantigens, and their applicability in diagnosis and disease prediction. Endocr Rev 2002;23:327–364.

    Article  PubMed  CAS  Google Scholar 

  16. Winqvist O, Karlsson FA, Kämpe O. 21-Hydroxylase, a major autoantigen in idiopathic Addison’s disease. Lancet 1992;339:1559–1562.

    Article  PubMed  CAS  Google Scholar 

  17. Bednarek J, Furmaniak J, Wedlock N, Kiso Y, Baumann-Antczak A, Fowler SSS, Krishnan H, Craft JA, Rees Smith B. Steroid 21-hydroxylase is a major autoantigen involved in adult onset autoimmune Addison’s disease. FEBS Lett 1992;309:51–55.

    Article  PubMed  CAS  Google Scholar 

  18. Falorni A, Nikoshkov A, Laureti S, Grenbäck E, Hulting AL, Casucci G, Santeusanio F, Brunetti P, Luthman H, Lernmark Ǻ. High diagnostic accuracy for idiopathic Addison’s disease with a sensitive radiobinding assay for autoantibodies against recombinat human 21-hydroxylase. J Clin Endocrinol Metab 1995;80:2752–2755.

    Article  PubMed  CAS  Google Scholar 

  19. Colls J, Betterle C, Volpato M, Prentice L, Smith BR, Furmaniak J. Immunoprecipitation assay for autoantibodies to steroid 21-hydroxylase in autoimmune adrenal diseases. Clin Chem 1995;41:375–380.

    PubMed  CAS  Google Scholar 

  20. Tanaka H, Perez MS, Powell M, Sanders JF, Sawicka J, Chen S, Prentice L, Asawa T, Betterle C, Volpato M, Rees Smith B, Furmaniak J. Steroid 21-hydroxylase autoantibodies: measurements with a new immunoprecipitation assay. J Clin Endocrinol Metab 1997;82:1440–1446.

    Article  PubMed  CAS  Google Scholar 

  21. Chen S, Sawicka J, Prentice L, Sanders J, Tanaka H, Petersen V, Betterle C, Volpato M, Roberts S, Powell M, Rees Smith B, Furmaniak J. Analysis of autoantibody epitopes on steroid 21-hydroxylase (21-OH) using a panel of monoclonal antibodies. J Clin Endocrinol Metab 1998;83:2977–2986.

    Article  PubMed  CAS  Google Scholar 

  22. Nikoshkov A, Falorni A, Lajic S, Laureti S, Wedell A, Lernmark Ǻ, Luthman H. A conformation-dependent epitope in Addison’s disease and other endocrinological autoimmune diseases maps to a carboxyl-terminal functional domain of human steroid 21-hydroxylase. J Immunol 1999;162:2422–2426.

    PubMed  CAS  Google Scholar 

  23. Furmaniak J, Kominami S, Asawa T, Wedlock N, Colls J, Rees-Smith B. Autoimmune Addison’s disease. Evidence for a role of steroid 21-hydroxylase autoantibodies in adrenal insufficiency. J Clin Endocrinol Metab 1994;79:1517–1521.

    Article  PubMed  CAS  Google Scholar 

  24. Boscaro M, Betterle C, Volpato M, Fallo F, Furmaniak J, Rees-Smith B, Sonino N. Hormonal responses during various phases of autoimmune adrenal failure: no evidence for 21-hydroxylase enzyme activity block in vivo. J Clin Endocrinol Metab 1996;81:2801–2804.

    Article  PubMed  CAS  Google Scholar 

  25. Laureti S, Candeloro P, Aglietti MC, Giordano R, Arvat E, Ghigo E, Santeusanio F, Falorni A. Dehydroepiandrosterone, 17α-hydroxyprogesterone and aldosterone responses to the low-dose (1 mg) ACTH test in subjects with preclinical adrenal autoimmunity. Clin Endocrinol 2002;57:677–683.

    Article  CAS  Google Scholar 

  26. Betterle C, Pra CD, Pedini B, Zanchetta R, Albergoni MP, Chen S, Furmaniak J, Smith BR. Assessment of adrenocortical function and autoantibodies in a baby born to a mother with autoimmune polyglandular syndrome Type 2. J Endocrinol Invest 2004;27:618–621.

    PubMed  CAS  Google Scholar 

  27. Nomura K, Depura H, Saruta T. Addison’s disease in Japan: characteristics and changes revealed in a nationwide survey. Intern Med 1994;33:602–604.

    Article  PubMed  CAS  Google Scholar 

  28. de Carmo Silva R, Kater CE, Dib SA, Laureti S, Forini F, Casentino A, Falorni A. Autoantibodies against recombinant human steroidogenic enzyme 21-hydroxylase, side-chain cleavage and 17 α-hydroxylase in Addison’s disease and autoimmune polyendocrine syndrome type III. Eur J Endocrinol 2000;142:187–194.

    Article  PubMed  Google Scholar 

  29. Falorni A, Laureti S, De Bellis A, Zanchetta R, Tiberti C, Arnaldi G, Bini V, Bizzarro A, Dotta F, Mantero F, Bellastella A, Betterle C, Santeusanio F. Italian Addison Network Study: update of diagnostic criteria for the etiological classification of primary adrenal insufficiency. J Clin Endocrinol Metab 2004;89:1598–1604.

    Article  PubMed  CAS  Google Scholar 

  30. Falorni, A, Laureti S, Candeloro P, Perrino S, Coronella C, Bizzarro A, Bellastella A, Santeusanio F, De Bellis A. Steroid-cell autoantibodies are preferentially expressed in women with premature ovarian failure who have adrenal autoimmunity. Fertil Steril 2002;78:270–279.

    Article  PubMed  Google Scholar 

  31. Welt CK, Falorni A, Taylor AE, Martin KA, Hall JE. Selective theca cell destruction accounts for the multifollicular development, decreased estradiol and elevated inhibin B levels in autoimmune premature ovarian failure. J Clin Endocrinol Metab 2005;90:3069–3076.

    Article  PubMed  CAS  Google Scholar 

  32. Tsigkou A, Marzotti S, Borges L, Brozzetti A, Candeloro P, Bacosi ML, Bini V, Petraglia F, Falorni A. High serum inhibin concentration discriminates autoimmune oophoritis from other forms of primary ovarian insufficiency. J Clin Endocrinol Metab 2008;93:1263–1269.

    Article  PubMed  CAS  Google Scholar 

  33. Falorni A, Brozzetti A, La Torre D, Tortoioli C, Gambelunghe G. The association of genetic polymorphisms and autoimmune Addison’s disease. Exp Rev Clin Immunol 2008;4:441–456.

    Article  CAS  Google Scholar 

  34. Yu L, Brewer KW, Gates S, Wu A, Wang T, Babu SR, Gottlieb PA, Freed BM, Noble J, Erlich HA, Rewers MJ, Eisenbarth GS. DRB1*04 and DQ alleles: expression of 21-hydroxylase autoantibodies and risk of progression to Addison’s disease. J Clin Endocrinol Metab 1999;84:328–335.

    Article  PubMed  CAS  Google Scholar 

  35. Myhre AG, Undlien DE, Løvås K, Uhlving S, Nedrebø BG, Fougner KJ, Trovik T, Sørheim JI, Husebye E. Autoimmune adrenocortical failure in Norway autoantibodies and human leukocyte antigen class II associations related to clinical features. J Clin Endocrinol Metab 2002;87:618–623.

    Article  PubMed  CAS  Google Scholar 

  36. Gambelunghe G, Kockum I, Bini V, De Giorgi G, Celi F, Betterle C, Giordano R, Libè R, Falorni A. Retrovirus-like long terminal repeat DQ-LTR13 and genetic susceptibility to type 1 diabetes mellitus and autoimmune Addison’s disease. Diabetes 2005;54:900–905.

    Article  PubMed  CAS  Google Scholar 

  37. Bieda K, Pani MA, Van der Auwera B, Seidl C, Tönjes RR, Gorus F, Usadel KH, Badenhoop K. A retroviral long terminal repeat adjacent to the HLA DQB1 gene (DQ-LTR13) modifies Type I diabetes susceptibility on high risk DQ haplotypes. Diabetologia 2002;45:443–447.

    Article  PubMed  CAS  Google Scholar 

  38. Pani MA, Seidl C, Bieda K, Seissler J, Krause M, Seifried E, Usadel KH, Badenhoop K. Preliminary evidence that an endogenous retroviral long-terminal repeat (LTR13) at the HLA-DQB1 gene locus confers susceptibility to Addison’s disease. Clin Endocrinol 2002;56:773–777.

    Article  CAS  Google Scholar 

  39. Rønningen KS, Keiding N, Green A, EURODIAB ACE Study Group. Correlations between the incidence of childhood-onset type I diabetes in Europe and HLA genotypes. Diabetologia 2001;44(Suppl 3):B51–B59.

    Article  PubMed  Google Scholar 

  40. Gambelunghe G, Falorni A, Ghaderi M, Laureti S, Tortoioli C, Santeusanio F, Brunetti P, Sanjeevi CB. Microsatellite polymorphism of the MHC class I chain-related (MIC-A and MIC-B) genes marks the risk for autoimmune Addison’s disease. J Clin Endocrinol Metab 1999;84:3701–3707.

    Article  PubMed  CAS  Google Scholar 

  41. Park YS, Sanjeevi CB, Robles D, Yu L, Rewers M, Gottlieb PA, Fain P, Eisenbarth GS. Additional association of intra-MHC genes, MICA and D6S273, with Addison’s disease. Tissue Antigens 2002;60:155–163.

    Article  PubMed  CAS  Google Scholar 

  42. Ghaderi M, Gambelunghe G, Tortoioli C, Brozzetti A, Jatta K, Gharizadeh B, De Bellis A, Pecori Giraldi F, Terzolo M, Betterle C, Falorni A. MHC2TA single nucleotide polymorphism and genetic risk for autoimmune adrenal insufficiency. J Clin Endocrinol Metab 2006;91:4107–4111.

    Article  PubMed  CAS  Google Scholar 

  43. Skinningsrud B, Husebye E, Pearce SH, McDonald DO, Brandal K, Bøe Wolff A, Løvas K, Egeland T, Undlien DE. Polymorphisms in CLEC16A and CIITA at 16p13 are associated with primary adrenal insufficiency. J Clin Endocrinol Metab 2008;93:3310–3317.

    PubMed  CAS  Google Scholar 

  44. Freeman M, Weetman AP. T and B cell reactivity to adrenal antigens in autoimmune Addison’s disease. Clin Exp Immunol 1992;88:275–279.

    Article  PubMed  CAS  Google Scholar 

  45. Hayashi Y, Hiyoshi T, Takemura T, Kurashima C, Hirokawa K. Focal lymphocytic infiltration in the adrenal cortex of the elderly: immunohistological analysis of infiltrating lymphocytes. Clin Exp Immunol 1989;77:101–105.

    PubMed  CAS  Google Scholar 

  46. Nerup J, Andersen V, Bendixen G. Anti-adrenal, cellular hypersensitivity in Addison’s disease. Clin Exp Immunol 1969;4:355–363.

    PubMed  CAS  Google Scholar 

  47. Nerup J, Andersen V, Bendixen G. Anti-adrenal, cellular hypersensitivity in Addison’s disease. IV. In vivo and in vitro investigations on the mitochondrial fraction. Clin Exp Immunol 1970;6:733–739.

    PubMed  CAS  Google Scholar 

  48. Rabinowe SL, Jackson RA, Dluhy RG, Williams GH. Ia-positive T lymphocytes in recently diagnosed idiopathic Addison’s disease. Am J Med 1984;77:597–601.

    Article  PubMed  CAS  Google Scholar 

  49. Kriegel MA, Lohmann T, Gabler C, Blank N, Kalden JR, Lorenz HM. Defective suppressor function of human CD4+CD25+ regulatory T cells in autoimmune polyglandular syndrome type II. J Exp Med 2004;199:1285–1291.

    Article  PubMed  CAS  Google Scholar 

  50. Rotondi M, Falorni A, De Bellis A, Laureti S, Ferruzzi P, Romagnani P, Buonamano A, Mannelli M, Santeusanio F, Bellastella A, Serio M. Elevated serum interferon-g inducible chemokine IP-10/CXCL10 in autoimmune primary adrenal insufficiency and in vitro expression in human adrenal cells primary cultures after stimulation with proinflammatory cytokines. J Clin Endocrinol Metab 2005;90:2357–2363.

    Article  PubMed  CAS  Google Scholar 

  51. Betterle C, Scalici C, Presotto F, Pedini B, Moro L, Rigon F, Mantero F. The natural history of adrenal function in autoimmune patients with adrenal autoantibodies. J Endocrinol 1988;117:467–475.

    Article  PubMed  CAS  Google Scholar 

  52. De Bellis A, Bizzarro A, Rossi R, Paglionico VA, Criscuolo T, Lombardi G, Bellastella A. Remission of subclinical adrenocortical failure in subjects with adrenal autoantibodies. J Clin Endocrinol Metab 1993;76:1002–1007.

    Article  PubMed  Google Scholar 

  53. Betterle C, Volpato M, Rees-Smith B, Furmaniak J, Chen S, Greggio NA, Sanzari M, Tedesco F, Pedini B, Boscaro M, Presotto F. I. Adrenal cortex and steroid 21-hydroxylase autoantibodies in adult patients with organ-specific autoimmune diseases: markers of low progression to clinical Addison’s disease. J Clin Endocrinol Metab 1997;82:932–938.

    Article  PubMed  CAS  Google Scholar 

  54. Laureti S, De Bellis A, Muccitelli VI, Calcinaro F, Bizzarro A, Rossi R, Bellastella A, Santeusanio F, Falorni A. Levels of adrenocortical autoantibodies correlate with the degree of adrenal dysfunction in subjects with preclinical Addison’s disease. J Clin Endocrinol Metab 1998;83:3507–3511.

    Article  PubMed  CAS  Google Scholar 

  55. Barker JM, Ide A, Hostetler C, Yu L, Miao D, Fain PR, Eisenbarth GS, Gottlieb PA. Endocrine and immunogenetic testing in individuals with type 1 diabetes and 21-hydroxylase autoantibodies: Addison’s disease in a high-risk population. J Clin Endocrinol Metab 2005;90:128–134.

    Article  PubMed  CAS  Google Scholar 

  56. Coco G, Dal Pra C, Presotto F, Albergoni MP, Canova C, Pedini B, Zanchetta R, Chen S, Furmaniak J, Rees Smith B, Mantero F, Betterle C. Estimated risk for developing autoimmune Addison’s disease in patients with adrenal cortex autoantibodies. J Clin Endocrinol Metab 2006;91:1637–1645.

    Article  PubMed  CAS  Google Scholar 

  57. Arvat E, Di Vito L, Laffranco F, Maccario M, Baffoni C, Rossetto R, Aimaretti G, Camanni F, Ghigo E. Stimulatory effect of adrenocorticotropin on cortisol, aldosterone, and dehydroepiandrosterone secretion in normal humans: dose–response study. J Clin Endocrinol Metab 2000;88:3141–3146.

    Article  Google Scholar 

  58. Laureti S, Arvat E, Candeloro P, Di Vito L, Ghigo E, Santeusanio F, Falorni A. Low dose (1 mg) ACTH test in the evaluation of adrenal dysfunction in pre-clinical Addison’s disease. Clin Endocrinol 2000;53:107–115.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Section of Internal Medicine and Endocrine & Metabolic Sciences, University of Perugia, Perugia, Italy

    Alberto Falorni

Authors
  1. Alberto Falorni
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Health Sciences Center, Children's Hospital, University of Colorado, East 9th Avenue 4200, Denver, 80262, Colorado, USA

    George S. Eisenbarth

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Falorni, A. (2011). Addison’s Disease. In: Eisenbarth, G. (eds) Immunoendocrinology: Scientific and Clinical Aspects. Contemporary Endocrinology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-60327-478-4_24

Download citation

  • DOI: https://doi.org/10.1007/978-1-60327-478-4_24

  • Published:

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-60327-477-7

  • Online ISBN: 978-1-60327-478-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation